Braftovi FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
Braftovi (encorafenib) is a kinase inhibitor indicated:
- in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Development Timeline for Braftovi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.